ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. ClearPoint Neuro has set its FY 2024 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.
ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) last posted its earnings results on Tuesday, March 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. ClearPoint Neuro had a negative net margin of 92.21% and a negative return on equity of 83.94%. The company had revenue of $6.81 million during the quarter, compared to analysts’ expectations of $6.40 million. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
ClearPoint Neuro Price Performance
NASDAQ:CLPT traded down $0.01 during mid-day trading on Tuesday, reaching $5.32. 7,179 shares of the company were exchanged, compared to its average volume of 143,975. The company has a fifty day moving average of $6.42 and a 200 day moving average of $6.36. The stock has a market cap of $144.01 million, a PE ratio of -5.86 and a beta of 0.89. ClearPoint Neuro has a 12 month low of $4.05 and a 12 month high of $10.57. The company has a quick ratio of 3.80, a current ratio of 4.87 and a debt-to-equity ratio of 0.47.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on CLPT
About ClearPoint Neuro
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
See Also
- Five stocks we like better than ClearPoint Neuro
- Profitably Trade Stocks at 52-Week Highs
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Hilton Demonstrates Asset Light is Right for Investors
- What Investors Need to Know About Upcoming IPOs
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.